Chemomab Therapeutics (CMMB) Competitors

$2.02 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.04 (+1.93%)

As of 05/22/2026 07:11 PM Eastern

CMMB vs. NBRV, IXHL, GOSS, INCR, and ZYBT

Should you buy Chemomab Therapeutics stock or one of its competitors? MarketBeat compares Chemomab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemomab Therapeutics include Nabriva Therapeutics (NBRV), Incannex Healthcare (IXHL), Gossamer Bio (GOSS), InterCure (INCR), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Chemomab Therapeutics compare to Nabriva Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Chemomab Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Chemomab Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Chemomab Therapeutics' return on equity of -89.03% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Chemomab Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,137.62%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Chemomab Therapeutics' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Nabriva Therapeutics	Neutral

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Chemomab Therapeutics beats Nabriva Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Incannex Healthcare?

Chemomab Therapeutics (NASDAQ:CMMB) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Chemomab Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, indicating that its stock price is 622% more volatile than the broader market.

Chemomab Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 1,137.62%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Chemomab Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Chemomab Therapeutics has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Incannex Healthcare	$90K	468.16	-$46.88M	-$1.55	N/A

Incannex Healthcare's return on equity of -81.01% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Incannex Healthcare	N/A	-81.01%	-76.11%

In the previous week, Incannex Healthcare had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1 mentions for Incannex Healthcare and 0 mentions for Chemomab Therapeutics. Incannex Healthcare's average media sentiment score of 0.63 beat Chemomab Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Incannex Healthcare	Positive

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Chemomab Therapeutics and Incannex Healthcare tied by winning 7 of the 14 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Chemomab Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.02	-$170.37M	-$0.79	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Gossamer Bio has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 7.2% of Gossamer Bio shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Gossamer Bio had 21 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 21 mentions for Gossamer Bio and 0 mentions for Chemomab Therapeutics. Gossamer Bio's average media sentiment score of 0.06 beat Chemomab Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Neutral
Chemomab Therapeutics	Neutral

Gossamer Bio currently has a consensus price target of $5.00, indicating a potential upside of 2,279.82%. Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,137.62%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Summary

Gossamer Bio beats Chemomab Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Chemomab Therapeutics compare to InterCure?

InterCure (NASDAQ:INCR) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

8.3% of InterCure shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Chemomab Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,137.62%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InterCure has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Chemomab Therapeutics has lower revenue, but higher earnings than InterCure. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.61	-$10.37M	$0.03	29.30
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

In the previous week, InterCure's average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Chemomab Therapeutics	Neutral

InterCure's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Summary

InterCure and Chemomab Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Zhengye Biotechnology?

Chemomab Therapeutics (NASDAQ:CMMB) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Zhengye Biotechnology's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Zhengye Biotechnology	N/A	N/A	N/A

Chemomab Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, indicating that its share price is 347% less volatile than the broader market.

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Chemomab Therapeutics' average media sentiment score of 0.00 equaled Zhengye Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
Zhengye Biotechnology	Neutral

Chemomab Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 1,137.62%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Chemomab Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Chemomab Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Zhengye Biotechnology	$16.64M	2.47	-$9.98M	N/A	N/A

Summary

Chemomab Therapeutics beats Zhengye Biotechnology on 7 of the 10 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.53M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.91	18.74	21.22	25.66
Price / Sales	N/A	323.98	562.28	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.36	7.09	10.31	7.14
Net Income	-$8.99M	$24.45M	$3.57B	$335.98M
7 Day Performance	30.32%	6.38%	6.43%	4.15%
1 Month Performance	25.47%	2.43%	3.57%	2.54%
1 Year Performance	-63.00%	62.98%	34.07%	35.06%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	2.1361 of 5 stars	$2.02 flat	$25.00 +1,137.6%	-63.0%	$14.53M	N/A	N/A	20	Gap Down
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70
IXHL Incannex Healthcare	0.909 of 5 stars	$3.70 -2.4%	N/A	-46.1%	$45.35M	$90K	N/A	3	Analyst Upgrade Gap Up
GOSS Gossamer Bio	2.7904 of 5 stars	$0.20 +3.3%	$5.00 +2,411.3%	-82.5%	$45.23M	$48.47M	N/A	180	Gap Down High Trading Volume
INCR InterCure	0.5401 of 5 stars	$0.85 +3.6%	N/A	-43.3%	$44.84M	$78.47M	28.33	350	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. NBRV, IXHL, GOSS, INCR, and ZYBT

How does Chemomab Therapeutics compare to Nabriva Therapeutics?

Summary

How does Chemomab Therapeutics compare to Incannex Healthcare?

Summary

How does Chemomab Therapeutics compare to Gossamer Bio?

Summary

How does Chemomab Therapeutics compare to InterCure?

Summary

How does Chemomab Therapeutics compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. NBRV, IXHL, GOSS, INCR, and ZYBT

How does Chemomab Therapeutics compare to Nabriva Therapeutics?

Which has better valuation & earnings, CMMB or NBRV?

Which has more risk & volatility, CMMB or NBRV?

Is CMMB or NBRV more profitable?

Do analysts rate CMMB or NBRV?

Does the media refer more to CMMB or NBRV?

Do institutionals & insiders hold more shares of CMMB or NBRV?

Summary

How does Chemomab Therapeutics compare to Incannex Healthcare?

Which has more risk and volatility, CMMB or IXHL?

Do analysts prefer CMMB or IXHL?

Which has preferable earnings and valuation, CMMB or IXHL?

Is CMMB or IXHL more profitable?

Does the media refer more to CMMB or IXHL?

Do insiders & institutionals have more ownership in CMMB or IXHL?

Summary

How does Chemomab Therapeutics compare to Gossamer Bio?

Which has better earnings & valuation, GOSS or CMMB?

Which has more volatility and risk, GOSS or CMMB?

Do institutionals and insiders hold more shares of GOSS or CMMB?

Does the media favor GOSS or CMMB?

Do analysts prefer GOSS or CMMB?

Is GOSS or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to InterCure?

Do insiders and institutionals hold more shares of INCR or CMMB?

Do analysts rate INCR or CMMB?

Which has more risk and volatility, INCR or CMMB?

Which has better valuation & earnings, INCR or CMMB?

Does the media favor INCR or CMMB?

Is INCR or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to Zhengye Biotechnology?

Is CMMB or ZYBT more profitable?

Which has more risk and volatility, CMMB or ZYBT?

Do insiders & institutionals believe in CMMB or ZYBT?

Does the media favor CMMB or ZYBT?

Do analysts rate CMMB or ZYBT?

Which has stronger earnings & valuation, CMMB or ZYBT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools